Avience Biomedicals IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Return Estimator (GMP*)
Financial Analysis
| Metric | 2024 | 2025 | Jan 2026 |
|---|---|---|---|
| Revenue | 24.37 | 45.97 | 41.94 |
| Expense | 21.43 | 36.17 | 34.06 |
| Profit (PAT) | 2.14 | 7.23 | 5.74 |
| Total Assets | 34.65 | 56.52 | 66.07 |
Promoters: Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 40,31,256 | 87.89% |
| Promoter Holding Post Issue | 54,85,056 | 64.59% |
Strengths & Risks
- Revenue grew 89% in the latest reported year.
- Solid profit margin — 15.7%.
- Strong return on equity — 50%.
No major red flags in the available data.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD). Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products. Its product range includes Rapid Test Kits, Biochemistry Analyzers and Reagents, Molecular Diagnostics, Hematology Analyzers, and Medical Devices. The company’s products are distributed to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas as well. Along with manufacturing, the firm also serves as a distributor and trader of medical equipment. Moreover, its manufacturing facility is located in Noida, Uttar Pradesh.
| Purpose | Amount (Cr) |
|---|---|
| Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | 15.96 |
| Funding the working capital requirements of the Company | 8.25 |
| General Corporate Purpose | - |
Resources & Documents
Avience Biomedicals Ltd., C-11, Block-C, Community Centre,, Janakpuri A-3,, Delhi, New Delhi, 110058
Avience Biomedicals has set a price band of Rs 196–Rs 208 per share for an issue size of Rs 30 crore. The SME issue is scheduled to open for subscription on June 18, 2026 — 3 days from now.
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD).
The issue is promoted by Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary with Fintellectual Corporate Advisors Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 2… (Rs 16 crore) and Funding the working capital requirements of the Company (Rs 8 crore).
On fundamentals, the company is posting revenue growth of 88.6%, a profit margin of 15.7%, return on equity of 49.9% in its most recent reported period.
All figures below — GMP history, subscription tiers, financials and peers — are aggregated from public disclosures. Always apply through your own broker after reading the RHP.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!